Loading…
Nephron Pharmaceuticals committed to minimum orders of over $400 million over 10 years from Sharps Technology, starting with about $30 million of revenue in the first year, with product delivery scheduled for Q1 2024.
Sharps Technology signed an asset purchase agreement to acquire Nephron Pharmaceuticals' InjectEZ specialty syringe manufacturing facility for $50 million, backed by a term sheet for up to $75 million in debt financing.
